Evaluation of the Potential Food Allergy Risks of Human Lactoferrin Expressed in Komagataella phaffii

Abstract

Prior to the introduction of novel food ingredients into the food supply, safety risk assessments are required, and numerous prediction models have been developed and validated to evaluate safety. The allergenic risk potential of Helaina recombinant human lactoferrin (rhLF, Effera™), produced in Komagataella phaffii (K. phaffii), was assessed by literature search, bioinformatics sequence comparisons to known allergens, glycan allergenicity assessment, and a simulated pepsin digestion model. The literature search identified no allergenic risk for Helaina rhLF, K. phaffii, or its glycans. Bioinformatics search strategies showed no significant risk for cross-reactivity or allergenicity between rhLF or the 36 residual host proteins and known human allergens. Helaina rhLF was also rapidly digested in simulated gastric fluid and its digestibility profile was comparable to human milk lactoferrin (hmLF), further demonstrating a low allergenic risk and similarity to the hmLF protein. Collectively, these results demonstrate a low allergenic risk potential of Helaina rhLF and do not indicate the need for further clinical testing or serum IgE binding to evaluate Helaina rhLF for risk of food allergy prior to introduction into the food supply.

Full Paper

Category
Published Papers
Journal
Frontiers in Immunology
Publication date
July 23, 2024
Authors
YA
Yanisa Anaya
Yanisa Anaya
Biomedical engineer; Associate/Entry-level Scientist at Helaina, contributing to allergenicity risk assessment of recombinant human lactoferrin.
RM
Raysa Rosario Martinez
Raysa Rosario Martinez
Associate Scientist in Nutritional Biology & Safety at Helaina, Inc., co-author on human lactoferrin food-allergy risk research.
RG
Richard E. Goodman
Richard E. Goodman
Research Professor, Food Allergy Research and Resource Program, University of Nebraska-Lincoln; expert in food allergy and GMO/novel-food risk assessment.
PJ
Philip Johnson
Philip Johnson
Associate Professor of Food Science & Technology, University of Nebraska-Lincoln (FARRP); specializes in mass spectrometry-based food allergen detection.
SV
Shashwat Vajpeyi
Shashwat Vajpeyi
VP of Bioprocess & Engineering at Helaina, holding a PhD in chemical engineering and overseeing scale-up to commercial production of effera lactoferrin.
XL
Xiaoning Lu
Xiaoning Lu
PhD analytical chemist; Head of Analytics and Testing at Helaina, developing analytical platforms for glycoprotein and food analysis.
RP
Ross D. Peterson
Ross D. Peterson
PhD; VP of Scientific and Regulatory Affairs at Helaina, leading regulatory strategy and safety/efficacy science for effera lactoferrin.
SW
Sarah M. Weyers
Sarah M. Weyers
Independent Scholar, San Diego, CA; co-author on Helaina's food allergy risk evaluation of recombinant human lactoferrin.
BB
Bella Breen
Bella Breen
Associate Scientist in Late Stage R&D at Helaina, Inc., co-author of the Helaina food-allergy-risk evaluation of recombinant human lactoferrin.
KN
Kahler Newsham
Kahler Newsham
Lead downstream/bioprocess engineer at Helaina (chemical engineering, Tufts University), works on purifying fermentation output into effera lactoferrin powder.
BS
Brian Scottoline
Brian Scottoline
M.D., Ph.D., Associate Professor of Pediatrics, Division of Neonatology, Oregon Health & Science University; neonatologist researching infant gut health and lactoferrin.
AC
Anthony J. Clark
Anthony J. Clark
Chief Technology Officer at Helaina, leading precision fermentation and strain development for effera human lactoferrin.
CM
Carrie-Anne Malinczak
Carrie-Anne Malinczak
PhD immunologist; Director/Head of Immunology at Helaina, Inc., co-author on Helaina recombinant human lactoferrin safety studies.

Ready to build the future?

effera® is more than an ingredient; it's a platform for innovation.
If you're ready to move beyond legacy ingredients and create a product that's truly aligned with human biology, we're ready to talk.